A clinical trial (NCT04275414) to explore bevacizumab, an anti-VEGF, in patients with COVID-19 has been registered with clear pathological rationale (“Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)” 2020). Here, VEGFA is linked to COVID-19.